Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder

Completed · Phase 3

Conditions studied: Hypercholesterolemia, Familial

In brief

The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To evaluate the efficacy and safety of the lipid drug Torcetrapib/atorvastatin in patients with genetically known disorder of extremely high cholesterol

Key facts

Study ID

NCT00134511

Run by

Pfizer

People needed

30

Starts

2005-03-01

Expected to finish

2005-11-01

Last updated by the study team

2007-11-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of Homozygous Familial Hypercholesterolemia

You may not qualify if…

• Women who are pregnant or lactating, or planning to become pregnant.
• Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid
• Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
• Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluationof response, or render unlikely that the subject would complete the study

Where it is running

• Pfizer Investigational Site — Boston, Massachusetts, United States
• Pfizer Investigational Site — Chicoutimi, Quebec, Canada
• Pfizer Investigational Site — Ste-Foy, Quebec, Canada
• Pfizer Investigational Site — Parktown, Johannesburg, South Africa
• Pfizer Investigational Site — Bloemfontein, South Africa
• Pfizer Investigational Site — Cape Town, South Africa

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.